Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Brian Sworder, MD PhD, David M. Kurtz, MD PhD, Charles Macaulay, MSc, BA, Matthew J. Frank, MD PhD, Stefan Alig, MD, Andrea Garofalo, BS, BA, Bita Sahaf, PhD, Mohammad Shahrokh Esfahani, Jay Y. Spiegel, MDFRCPC, Jean Oak, MD PhD, Sara Beygi, MD, Michael C. Jin, BS, Jacob J Chabon, Michael S. Khodadoust, MD PhD, Robbie G. Majzner, MD, Crystal L. Mackall, MD, Maximilian Diehn, MD PhD, David B Miklos, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 550.

https://doi.org/10.1182/blood-2019-129015

Published: 2019

Journal Articles

Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction

Liora M Schultz, MD, Shabnum Patel, PhD, Sneha Ramakrishna, MD, Alice Bertaina, MD PhD, Neehar Bhatia, Jean Oak, MD PhD, Robbie G. Majzner, MD, Christina Baggott, RN, PhD, Kara L. Davis, DO, Crystal L. Mackall, MD, Steven A Feldman, PhD

Blood (2019) 134 (Supplement_1): 4471.

https://doi.org/10.1182/blood-2019-129436

Published: 2019

Journal Articles

Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 576.

https://doi.org/10.1182/blood-2018-99-113261

Published: 2018

Journal Articles

Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies

Nasheed Hossain, MD, Bita Sahaf, PhD, Matthew Abramian, PhD, Jay Y. Spiegel, MD, Katie Kong, Stephen Kim, Sharon Mavroukakis, Jean Oak, MD PhD, Yasodha Natkunam, MD PhD, Everett H Meyer, MD PhD, Matthew J. Frank, MD PhD, Steven A Feldman, PhD, Steven R. Long, MD, Haiying Qin, MS, Terry J. Fry, MD, Lori S Muffly, MD, Crystal L. Mackall, MD, David B. Miklos, MD PhD

Blood (2018) 132 (Supplement 1): 490.

https://doi.org/10.1182/blood-2018-99-110142

Published: 2018

Journal Articles

Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy

Jean Oak, MD PhD, Jay Y. Spiegel, MD, Bita Sahaf, PhD, Yasodha Natkunam, MD PhD, Steven R. Long, MD, Nasheed Hossain, MD, Crystal L. Mackall, MD, Katherine A. Kong, David B. Miklos, MD PhD

Blood (2018) 132 (Supplement 1): 4656.

https://doi.org/10.1182/blood-2018-99-120206

Published: 2018

NARROW

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction

Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma

Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies

Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy

Email alerts

ASH Publications

American Society of Hematology

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction

Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma

Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies

Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only